NASDAQ$ORIC

ORIC Pharmaceuticals Inc · Q2 2019 earnings

Q2 2019 earnings · · Investor relations

Headline financials

EPS (adj)

-$0.31

No prior period
Net Income

-$5.97M

No prior period
Operating Income

-$6.36M

No prior period
Gross Profit

$0.00

No prior period
R&D Expense

$5.04M

No prior period

Revenue & EPS history

ORIC Pharmaceuticals · Revenue · Quarterly

$0

Q2 2025

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports

Historical avg

+1.2%

Avg return

Earnings day

+1.1%

Avg return

5 days after

+8.0%

Avg return

30 days after

57%

13 / 23 earnings

Positive

+14.7%

Q2 2023

Best reaction

-29.8%

Q4 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+14.7%+14.9%+5.7%
Q3 2025+0.3%-5.8%-23.1%
Q2 2025-1.0%-7.9%+8.9%
Q1 2025+8.7%+25.8%+98.9%
Q4 2024+0.8%+2.1%-43.5%
Q3 2024-0.3%-17.5%-18.2%
Q1 2024-1.0%-7.4%-5.6%
Q4 2023-4.5%+0.7%-33.3%
Q3 2023-3.2%-11.9%+26.4%
Q2 2023+14.7%+13.8%+17.3%
Q1 2023-0.4%+0.1%+11.4%
Q4 2022+5.3%+14.8%+39.5%
Q3 2022+2.8%+17.9%+35.4%
Q2 2022+3.2%-2.1%-26.4%
Q1 2022-3.4%-4.4%+52.0%
Q4 2021-29.8%-33.0%-42.6%
Q3 2021+7.1%+8.4%-7.1%
Q2 2021+9.4%+13.6%+45.2%
Q1 2021+2.1%+6.1%-17.0%
Q4 2020-6.2%-7.6%-10.2%
Q3 2020+3.8%+4.4%+55.6%
Q2 2020+12.5%+12.4%+7.8%
Q1 2020-8.7%-11.3%+7.3%
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro